GlobeNewsWire
17 Aug 2026, 05:00 UTC · 11w ago
Impact · against what's priced in
Positive Phase 3 results for efgartigimod in autoimmune myositis create a new growth catalyst for argenx and Zai Lab. The trial's success in IMNM—a population with no currently approved treatments—provides a high-conviction path toward regulatory approval and market expansion.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
argenx announced positive topline results from the Phase 3 ALKIVIA trial of efgartigimod in adults with autoimmune myositis, meeting its primary endpoint (p=0.0011).
More positive than 99% of claims this week
The treatment showed clinical improvement in both Immune-Mediated Necrotizing Myopathy (IMNM) and Dermatomyositis (DM), with IMNM previously having no approved treatment options.
Continue reading
5 related stories
The Phase 3 ALKIVIA trial met its primary endpoint (p=0.0011), demonstrating efficacy in both Dermatomyositis and Immune-Mediated Necrotizing Myopathy (IMNM), the latter of which currently has no approved treatment options.
Read from the article alone
No priced-in read yet
As the exclusive licensee for efgartigimod in Greater China, Zai Lab benefits from the successful Phase 3 data which increases the probability of commercialization in its territory.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 92% of claims this week
Efgartigimod was reported as well-tolerated with a safety profile consistent with previous studies.
More positive than 60% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced positive topline results from a Phase 3 trial for efgartigimod in autoimmune myositis, meeting its primary endpoint.
More positive than 64% of ticker scores this week
Zai Lab holds an exclusive license for the drug in Greater China and supported the successful trial via patient recruitment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
6h ago
—
No price for ZAI right now — the quote feed didn't answer.
ZAI chart →+8.1%
Price agrees with the score
$920.38 vs $851.29 close before publication (Aug 14) · not market-adjusted
ARGX chart →
